vs
Side-by-side financial comparison of COMSCORE, INC. (SCOR) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $93.5M, roughly 1.4× COMSCORE, INC.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -1.5%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 3.8%).
Comscore, Inc. is an American-based global media measurement and analytics company providing marketing data and analytics to enterprises, advertising agencies, brand marketers, and publishers.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
SCOR vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $93.5M | $129.7M |
| Net Profit | $3.0M | — |
| Gross Margin | 41.0% | 98.0% |
| Operating Margin | 7.0% | -25.0% |
| Net Margin | 3.2% | — |
| Revenue YoY | -1.5% | 73.4% |
| Net Profit YoY | -3.7% | — |
| EPS (diluted) | $9.50 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $93.5M | $129.7M | ||
| Q3 25 | $88.9M | $164.9M | ||
| Q2 25 | $89.4M | $114.4M | ||
| Q1 25 | $85.7M | $81.7M | ||
| Q4 24 | $94.9M | $74.8M | ||
| Q3 24 | $88.5M | $62.9M | ||
| Q2 24 | $85.8M | $54.1M | ||
| Q1 24 | $86.8M | $41.4M |
| Q4 25 | $3.0M | — | ||
| Q3 25 | $453.0K | $25.7M | ||
| Q2 25 | $-9.5M | $-12.8M | ||
| Q1 25 | $-4.0M | $-41.2M | ||
| Q4 24 | $3.1M | — | ||
| Q3 24 | $-60.6M | $-54.8M | ||
| Q2 24 | $-1.7M | $-70.4M | ||
| Q1 24 | $-1.1M | $-136.1M |
| Q4 25 | 41.0% | 98.0% | ||
| Q3 25 | 40.6% | 99.0% | ||
| Q2 25 | 40.6% | 98.7% | ||
| Q1 25 | 39.6% | 94.3% | ||
| Q4 24 | 42.4% | 96.6% | ||
| Q3 24 | 41.2% | 97.4% | ||
| Q2 24 | 39.5% | 96.2% | ||
| Q1 24 | 42.3% | 96.4% |
| Q4 25 | 7.0% | -25.0% | ||
| Q3 25 | 1.9% | 15.1% | ||
| Q2 25 | -1.9% | -11.1% | ||
| Q1 25 | -2.4% | -52.2% | ||
| Q4 24 | 4.1% | -81.2% | ||
| Q3 24 | -67.4% | -89.3% | ||
| Q2 24 | -2.2% | -125.1% | ||
| Q1 24 | -2.2% | -336.5% |
| Q4 25 | 3.2% | — | ||
| Q3 25 | 0.5% | 15.6% | ||
| Q2 25 | -10.6% | -11.1% | ||
| Q1 25 | -4.7% | -50.4% | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | -68.5% | -87.1% | ||
| Q2 24 | -2.0% | -130.1% | ||
| Q1 24 | -1.2% | -328.9% |
| Q4 25 | $9.50 | $0.04 | ||
| Q3 25 | $-0.86 | $0.28 | ||
| Q2 25 | $-2.73 | $-0.14 | ||
| Q1 25 | $-1.66 | $-0.47 | ||
| Q4 24 | $-0.47 | $-0.71 | ||
| Q3 24 | $-12.79 | $-0.70 | ||
| Q2 24 | $-1.19 | $-0.91 | ||
| Q1 24 | $-1.08 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.6M | $93.0M |
| Total DebtLower is stronger | $41.5M | — |
| Stockholders' EquityBook value | $111.4M | $114.8M |
| Total Assets | $407.7M | $605.2M |
| Debt / EquityLower = less leverage | 0.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.6M | $93.0M | ||
| Q3 25 | $26.7M | $110.9M | ||
| Q2 25 | $26.0M | $75.2M | ||
| Q1 25 | $31.0M | $61.9M | ||
| Q4 24 | $29.9M | $58.5M | ||
| Q3 24 | $20.0M | $36.4M | ||
| Q2 24 | $14.7M | $32.3M | ||
| Q1 24 | $18.7M | $43.3M |
| Q4 25 | $41.5M | — | ||
| Q3 25 | $41.4M | — | ||
| Q2 25 | $41.3M | — | ||
| Q1 25 | $41.3M | — | ||
| Q4 24 | $41.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $111.4M | $114.8M | ||
| Q3 25 | $-26.3M | $73.6M | ||
| Q2 25 | $-21.7M | $32.7M | ||
| Q1 25 | $-13.5M | $32.8M | ||
| Q4 24 | $-8.3M | $59.1M | ||
| Q3 24 | $-2.7M | $-30.5M | ||
| Q2 24 | $45.8M | $15.1M | ||
| Q1 24 | $51.4M | $74.1M |
| Q4 25 | $407.7M | $605.2M | ||
| Q3 25 | $406.9M | $538.6M | ||
| Q2 25 | $415.9M | $555.3M | ||
| Q1 25 | $421.5M | $548.8M | ||
| Q4 24 | $430.2M | $594.1M | ||
| Q3 24 | $412.5M | $504.4M | ||
| Q2 24 | $474.1M | $551.1M | ||
| Q1 24 | $477.7M | $663.5M |
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.2M | $60.7M |
| Free Cash FlowOCF − Capex | $2.9M | — |
| FCF MarginFCF / Revenue | 3.1% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | 1.07× | — |
| TTM Free Cash FlowTrailing 4 quarters | $21.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.2M | $60.7M | ||
| Q3 25 | $9.5M | $14.3M | ||
| Q2 25 | $932.0K | $5.0M | ||
| Q1 25 | $9.1M | $-42.2M | ||
| Q4 24 | $-10.0M | $-35.7M | ||
| Q3 24 | $12.5M | $-42.5M | ||
| Q2 24 | $8.7M | $-40.2M | ||
| Q1 24 | $6.9M | $-119.0M |
| Q4 25 | $2.9M | — | ||
| Q3 25 | $9.4M | $14.2M | ||
| Q2 25 | $787.0K | — | ||
| Q1 25 | $8.7M | — | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $12.4M | — | ||
| Q2 24 | $8.5M | $-40.3M | ||
| Q1 24 | $6.6M | — |
| Q4 25 | 3.1% | — | ||
| Q3 25 | 10.5% | 8.6% | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 10.1% | — | ||
| Q4 24 | -10.8% | — | ||
| Q3 24 | 14.0% | — | ||
| Q2 24 | 10.0% | -74.5% | ||
| Q1 24 | 7.6% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | 0.1% | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | 0.0% | ||
| Q2 24 | 0.2% | 0.2% | ||
| Q1 24 | 0.3% | 0.0% |
| Q4 25 | 1.07× | — | ||
| Q3 25 | 20.96× | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -3.19× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
